A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
about
Autophagy and urothelial carcinoma of the bladder: A reviewSTAT3: A Novel Molecular Mediator of Resistance to ChemoradiotherapyA nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy.Predicting the Survival Time for Bladder Cancer Using an Additive Hazards Model in Microarray Data.Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions.CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer.Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.Expression of cyclin d1 and its association with disease characteristics in bladder cancer.MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer.Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster.Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype CarcinomasBlocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States.PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.Adjuvant Chemotherapy Correlates with Improved Survival after Radical Cystectomy in Patients with pT3b (Macroscopic Perivesical Tissue Invasion) Bladder CancerPredictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over timeDisease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a CohortTreatment Response Assessment for Bladder Cancer on CT Based on Computerized Volume Analysis, World Health Organization Criteria, and RECIST.Performance of simultaneous high temporal resolution quantitative perfusion imaging of bladder tumors and conventional multi-phase urography using a novel free-breathing continuously acquired radial compressed-sensing MRI sequenceTreatment Decision Making in Patients with Bladder Cancer.Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?Bladder Cancer Segmentation in CT for Treatment Response Assessment: Application of Deep-Learning Convolution Neural Network-A Pilot Study.Aberrant expression of microRNAs in bladder cancer.Targeted therapies in bladder cancer: an overview of in vivo research.Urinary Bladder Cancer Staging in CT Urography using Machine Learning.Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.Treatment of muscle-invasive bladder cancer: A systematic review.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancerPartial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience.Variations in Preoperative Use of Bone Scan Among Medicare Beneficiaries Undergoing Radical Cystectomy.Nivolumab for the treatment of bladder cancer.Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.
P2860
Q26744142-1530437A-D51E-4DEC-82BC-121572F34630Q27003190-020CC0B3-BB85-4156-9E8C-A1FDAB385E15Q30981992-CAABEFA2-B2CC-4168-9360-4AD0162A8EB1Q31085072-826503BC-D0AF-402F-81C9-E52B8B1BCDFAQ33662842-B7DA671A-B1D1-4F2E-AE19-9B05839833EBQ33758673-86FAD2D2-0158-4766-A588-CF2D925F6C2CQ33788042-121F74E0-99CE-4527-87F6-524FD977792CQ33994334-B0AE6D09-B20B-4BD2-A1A7-7C8301D71307Q34005450-F429E196-9776-4A97-AB93-534E0D95CBFFQ34227727-7EE4DD39-CFFB-47DD-B0E9-D9A89F266F8CQ34435978-23B16165-DA34-4025-8DB8-9D7FE49FE262Q34658794-74CBE4F8-F6C6-4F56-8D8F-18493FF7EF3EQ34993621-54153432-1676-45FB-97A0-217C1ED9D5A8Q35092566-BB0CC889-8A0C-40A3-A3FC-96EF331DC224Q35180823-AA75845E-0B17-447D-A7FC-3E2C6B1B9A6AQ35568071-545FFEB8-30C1-408D-980D-53FA3604FECAQ35612218-0E4DC339-5C0C-447C-9942-70990C1627BBQ35735937-E6344E9E-733E-4968-A758-E88579A3878FQ35748060-991C762C-3FE6-44A4-B07F-763C3EFDB549Q35776939-1A80CB4F-63AD-4366-A360-17A5AC39CB1EQ35856850-468CEA4A-159C-41A9-A282-17CA43C37FBAQ35956231-831C6A08-63DD-412F-B895-662C82788851Q36221402-6BA1BD9C-9A17-4EA9-8693-A32C19CA6026Q36686291-53F95EC0-5A61-489E-83A5-926F59B97A0EQ36977504-063304C9-DEBF-42F4-ABFC-5C31899E590BQ37053944-938D5074-21C2-4F8D-9CD1-2DE199F931B6Q37411206-C8FBBCD6-23BE-44F9-AD02-5002E39DCEEBQ37530344-1F65B4DD-1756-40E8-A2FB-9F7E0BB18A93Q37590311-A94F4B41-D3A3-4C7E-B9B7-177AF5240774Q38109811-D88A09E5-ACE1-4545-A71E-2F95B4C11379Q38590471-0A821947-BD14-4CCF-831B-613EBB5A76A0Q38635207-E97CED18-A039-4DA7-BEAA-2350C26EB120Q38654974-194A2F89-D887-4451-AB48-A083C66ACD57Q38698579-7116D536-407B-4D0B-9F2B-3FABEF237D97Q38701535-8715A9D6-7B1A-47DC-BA3D-2B0CC1821EAEQ38764114-B6F0A646-15DA-4DF5-9F5B-41B5CD1726BBQ38902028-2379063A-FE12-402A-ACC8-97501F964795Q38941333-81299F22-F2F7-4958-B6E0-59929996E4A2Q39454030-B0439ED1-7FC2-4F0B-8BB2-941DEF3072DCQ40233664-A7DFFFD3-19EB-4DF4-9A8F-7DDA05161015
P2860
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A systematic review of neoadju ...... uscle-invasive bladder cancer.
@en
type
label
A systematic review of neoadju ...... uscle-invasive bladder cancer.
@en
prefLabel
A systematic review of neoadju ...... uscle-invasive bladder cancer.
@en
P2093
P1433
P1476
A systematic review of neoadju ...... uscle-invasive bladder cancer.
@en
P2093
Bernard H Bochner
Cora N Sternberg
Guru Sonpavde
Joaquim Bellmunt
Joshua J Meeks
Malcolm Mason
Matthew D Galsky
Noah M Hahn
Noel W Clarke
Seth P Lerner
P304
P356
10.1016/J.EURURO.2012.05.048
P407
P577
2012-06-01T00:00:00Z